Therefore, the 3.7‐fold downregulation of Gpr37l1 in the hippocampus of CRSTumor mice may represent a novel drug target for neuroprotection and improving cognitive function in stressed patients diagnosed with breast cancer. This evidence concerns the gene GPR37L1 and breast carcinoma.